R&G PharmaStudies Co Equity
The The Equity of R&G PharmaStudies Co (301333.SZ) as of Nov 4, 2026 is 1.97 B CNY. In the previous year, The Equity was 1.83 B CNY — a change of 7.40% (higher).
Get this data via API
Financial Data API
Equity
1.97 BCNY
YoY
7.40%
Last updated:
In 2025, R&G PharmaStudies Co's equity was 1.97 B CNY, a 7.40% increase from the 1.83 B CNY equity in the previous year.
The R&G PharmaStudies Co Equity history
3 Years
10 Years
25 Years
Max
| YEAR | Equity | YoY |
|---|---|---|
| 1.97 BCNY | +7.40% | |
| 1.83 BCNY | +4.81% | |
| 1.75 BCNY | +10.12% | |
| 1.59 BCNY | +275.77% | |
| 422.53 MCNY | +30.88% | |
| 322.83 MCNY | +35.79% | |
| 237.74 MCNY | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
R&G PharmaStudies Co Stock analysis
Equity Details
Analyzing R&G PharmaStudies Co's Equity
R&G PharmaStudies Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding R&G PharmaStudies Co's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating R&G PharmaStudies Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
R&G PharmaStudies Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in R&G PharmaStudies Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about R&G PharmaStudies Co stock
The Equity of R&G PharmaStudies Co is 1.97 B CNY in 2025.
The Equity of R&G PharmaStudies Co changed from 1.83 B CNY to 1.97 B CNY, representing a 7.40% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of The Equity R&G PharmaStudies Co since 2006 – with annual values, charts, and detailed analysis.
The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's R&G PharmaStudies Co historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — R&G PharmaStudies Co
All Key Metrics — R&G PharmaStudies Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth